MindMed announced that the FDA granted breakthrough designation to its MM120 program for the treatment of generalized anxiety disorder, and its Phase 2b trial of MM120 met its key secondary endpoint.
AI Assistant
MIND MEDICINE (MINDMED) INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.